Cáncer de tiroides

+ -Text Size

Otros recursos y referencias TEMAS

Referencias: Guía detallada del cáncer de tiroides

Ain K, Lee C, Holbrook K, et al. Lenalidomide in distantly metastatic, rapidly progressive and radioiodine unresponsive thyroid carcinomas: Preliminary results. J Clin Oncol. 2008:26 (May 20 suppl). Abstract 6027.

American Cancer Society. Cancer Facts & Figures 2012. Atlanta, Ga: American Cancer Society; 2012.

American Cancer Society. Cancer Facts & Figures 2013. Atlanta, Ga: American Cancer Society; 2013.

American Joint Committee on Cancer. Thyroid. In: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010:87−92.

American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, Evans DB, et al. Cáncer medular tiroideo: Management guidelines of the American Thyroid Association. Thyroid. 2009;19:565−612.

American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167−1214.

Bible KC, Suman VJ, Molina JR, et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: Results of a phase 2 consortium study. Lancet Oncol. 2010;11:962−972.

Carling T, Udelsman R. Thyroid tumors. In: DeVita VT, Hellman S, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2011.

Carr LL, Mankoff DA, Goulart BH, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010;16:5260−5268.

Cohen E, Rosen L, Vokes E et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study. J Clin Oncol. 2008;26:4708−4713.

Fagin JA. Challenging dogma in thyroid cancer molecular genetics — role of RET/PTC and BRAF in tumor initiation. J Clin Endocrinol Metab. 2004;89:4280−4284.

Gupta-AbramsonV, Troxel A, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008:26:4714−4719.

Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2009, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2009/, based on November 2011 SEER data submission, posted to the SEER web site, April 2012.

Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol. 2009;27:1675−1684.

Kurzrock R, Sherman SI, Ball DW, et al. Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011:29:2660-2666.

Lal G, D’Orosio T, McDougall R, Wiegel RJ. Cancer of the endocrine system. In: Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG, eds. Abeloff's Clinical Oncology. 4th ed. Philadelphia, Pa: Elsevier; 2008:1271−1305.

National Cancer Institute. Physician Data Query (PDQ). Thyroid Cancer Treatment. 2012. Accessed at www.cancer.gov/cancertopics/pdq/treatment/thyroid/healthprofessional on August 16, 2012.

National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: Thyroid Carcinoma. V.3.2012. Accessed at www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf on August 16, 2012.

Sherman SI, Wirth LJ, Droz J-P, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008;359:31−42

Schlumberger MJ, Elisei R, Bastholt L, et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol. 2009;27:3794−3801.

Vaisman A, Orlov S, Yip J, et al. Application of post-surgical stimulated thyroglobulin for radioiodine remnant ablation selection in low-risk papillary thyroid carcinoma. Head Neck. 2010;32:689−698.

Fecha de última actualización: 02/04/2013
Fecha de último cambio o revisión: 02/04/2013